After anti-CTLA-4 mAb treatment, the ratio of Teffs to Tregs was positively correlated with treatment response depending on the presence of macrophages expressing the Fcγ receptor (95), and the use of anti-CTLA4 antibodies with an enhanced Fcγ R binding profile is recommended to achieve robust anti-tumour responses and improved survival (96). Here, CTLA4 is linked to neoplasm.